HS 370
Alternative Names: HS-370Latest Information Update: 31 Oct 2025
At a glance
- Originator 35Pharma
- Class Recombinant fusion proteins
- Mechanism of Action Activin inhibitors; Growth differentiation factor inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 16 Sep 2025 Preclinical trials in Unspecified in Canada (Parenteral), prior to September 2025 (35Pharma website, September 2025)